Year: 2024

eFFECTOR Therapeutics Announces Topline Results of Phase 2 KICKSTART Trial of Tomivosertib Combined with Pembrolizumab in Non-Small Cell Lung Cancer

SOLANA BEACH, Calif. and REDWOOD CITY, Calif., April 04, 2024 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader...

OrthoPediatrics Corp. to Highlight its Pediatric Scoliosis Solutions at 8th Annual International Children’s Spine Symposium (ICSS)

WARSAW, Ind., April 04, 2024 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics”) (NASDAQ: KIDS), a company focused exclusively on advancing the...

Tempest Announces Publication of Positive Data from Phase 1 Trial of TPST-1120 in Patients with Advanced Solid Tumors in Journal of Cancer Research Communications

TPST-1120, a first-in-class, oral, selective PPAR⍺ antagonist, demonstrates clinical activity in PD-1 inhibitor refractory and immune compromised cancersBased on subsequent...

GE HealthCare Introduces Caption AI on Vscan Air SL Wireless Handheld Ultrasound System to Help More Clinicians Capture Diagnostic-Quality Cardiac Images

Caption AI on Vscan Air SL expands access to cardiac care by enabling more medical professionals to feel confident acquiring...

error: Content is protected !!